Paramount Rx, Inc. v. Duggan

2015 NCBC 30
CourtNorth Carolina Business Court
DecidedMarch 27, 2015
Docket14-CVS-13216
StatusPublished

This text of 2015 NCBC 30 (Paramount Rx, Inc. v. Duggan) is published on Counsel Stack Legal Research, covering North Carolina Business Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Paramount Rx, Inc. v. Duggan, 2015 NCBC 30 (N.C. Super. Ct. 2015).

Opinion

Paramount Rx, Inc. v. Duggan, 2015 NCBC 30.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION COUNTY OF WAKE 14 CVS 13216

PARAMOUNT RX, INC., ) ) Plaintiff, ) ) v. ) ) ORDER ROBERT E. DUGGAN and ) AGELITY, INC., ) ) Defendants. ) )

{1} THIS MATTER is before the Court on Plaintiff’s Motion for Limited Expedited Discovery (“Plaintiff’s Motion”) and Defendants’ Motion to Dismiss, or in the Alternative, to Stay (“Defendants’ Motion”). For the reasons expressed below, Plaintiff’s Motion is DENIED, Defendants’ Motion is GRANTED IN PART and DEFERRED IN PART, as a result of which this action is STAYED.

Womble Carlyle Sandridge & Rice, LLP by Christopher W. Jones and Marina C. Carreker for Plaintiff Paramount Rx, Inc.

Ellis & Winters LLP by Leslie C. Packer and James M. Weiss for Defendants Robert E. Duggan and Agelity, Inc.

Gale, Chief Judge.

I. THE PARTIES

{2} Plaintiff Paramount Rx, Inc. (“Plaintiff” or “Paramount”) is a Delaware pharmacy benefits management corporation with its principal place of business in Cary, North Carolina. (Am. Compl. ¶ 5.) Nonparty Philip Escaldi (“Escaldi”) is Paramount’s President. (Am. Compl. ¶ 6.) Nonparty Michael Sallusto (“Sallusto”) is Paramount’s Executive Vice President. (Am. Compl. ¶ 28.) {3} Defendant Agelity, Inc. (“Agelity”) is a Delaware pharmacy benefits corporation that competes with Paramount and has its principal place of business in Melville, New York. (Am. Compl. ¶ 7.) Escaldi and Sallusto were formerly associated with Agelity. {4} Defendant Robert E. Duggan (“Duggan”) is Agelity’s President and resides in New York. (Am. Compl. ¶ 9.)

II. PROCEDURAL HISTORY

{5} Paramount initiated this action by filing its Complaint on October 1, 2014, accompanied by a Motion for Preliminary Injunction and Temporary Restraining Order and a Notice of Designation, pursuant to which the case was designated as a complex business case. The case was assigned to the undersigned on October 2, 2014. {6} Plaintiff seeks monetary and injunctive relief. The gravamen of Plaintiff’s Complaint is that Agelity and Duggan, in his capacity as Agelity’s President, have made and may continue to make defamatory statements to customers in the marketplace within which Paramount and Agelity compete. Paramount alleges that it was unaware of Defendants’ wrongful statements until it learned of them during a May 2014 deposition of Charles Myrick (“Myrick”), the President of American Consultants, Rx. (“American Consultants”), taken in New York litigation. Myrick testified that the statements began as early as late 2009, continued thereafter, and were factors that prevented American Consultants from entering into a business relationship with Paramount. (Am. Compl. ¶¶ 37–41.) {7} Prior to considering Plaintiff’s request for preliminary injunctive relief, the Court raised an initial inquiry whether any injunctive relief would be barred by the doctrine of prior restraint, grounded in the First Amendment of the United States Constitution. The parties filed memoranda addressing this threshold issue on October 21, 2014, discussing the principle that the prior restraint doctrine may apply less stringently to commercial speech, provided that the party seeking an injunction can demonstrate a pattern of defamatory commercial speech. After reviewing the briefs and authorities cited, the Court elected not to deny any possibility of a preliminary injunction, but expressed doubt that Plaintiff could satisfy the necessary evidentiary requirement of a pattern. {8} In response, Plaintiff filed a verified Amended Complaint on October 24, 2014, alleging additional statements beyond those made to Myrick, and followed on October 30, 2014, with its Motion for Limited Expedited Discovery, seeking limited discovery to further develop a record upon which to seek injunctive relief. Later, on December 4, 2014, Plaintiff sought to expedite discovery regarding Duggan’s challenge to personal jurisdiction. {9} Defendants filed their Motion on November 26, 2014. In addition to moving to dismiss all claims, Defendants alternatively urge the Court to stay this proceeding pursuant to subsection 1-75.12(a) of the North Carolina General Statutes in deference to two lawsuits that have been pending in New York (the “New York Actions”). {10} The Court held a status conference on December 5, 2014, in part to further inquire into the nature and status of the New York Actions, after which the Court accepted supplemental filings related to Defendants’ motion to stay. The Court reserved any briefing or consideration of Defendants’ motion to dismiss. {11} The Court heard argument regarding the motion to stay on January 15, 2015. At the hearing, the Court requested that Plaintiff further specify the limited discovery topics it wished to pursue on an expedited basis, including topics that would be addressed in a deposition of Defendant Duggan. Plaintiff complied by submitting its January 20, 2015, letter. {12} The Motions are then ripe and ready for ruling, except to the extent that Defendants’ Motion seeks dismissal, as the Court has continued to defer any briefing or consideration of that aspect of Defendants’ Motion.

III. THE PENDING ACTIONS

{13} Paramount’s primary complaint in this action is that Agelity and Duggan have made and may continue to make false, misleading, and malicious statements regarding Escaldi and Sallusto in order to cause companies to refrain from doing business with Paramount. Paramount is the sole plaintiff in this action. It seeks damages for past statements and an injunction against future statements. In part, Paramount complains of statements made to Myrick for the purposes of causing American Consultants to fail to do business with Paramount. {14} There are two prior pending New York cases. The first of the New York Actions was filed on November 30, 2011, and brought by Agelity and Duggan against Escaldi, but not Paramount. Agelity, Inc. v. Escaldi, No.: 11-3654 (N.Y. filed Nov. 30, 2011) (the “Escaldi Action”) (Defs.’ Mem. Supp. Mot. Stay or in Alternative Dismiss (“Defs.’ Mem. Supp.”) Ex. A.) The Escaldi Action complaint is grounded on a Settlement Agreement between Agelity and Escaldi entered after Escaldi’s employment with Agelity ended, resolving claims and selling Escaldi’s interest in Agelity. (Defs.’ Mem. Supp. Ex. A ¶¶ 12–24.) Agelity and Duggan seek damage for Escaldi’s breach of the Settlement Agreement, and particularly its nondisparagement clause (Defs.’ Mem. Supp. Ex. A ¶ 20) and the agreement not to divulge confidential information. (Defs.’ Mem. Supp. Ex. A ¶ 22.) Escaldi counterclaimed for breach of the nondisparagement provision of the Settlement Agreement, complaining of Duggan’s defamatory statements to Myrick and Paramount’s loss of American Consultants as a potential customer. (See Defs.’ Mem. Supp. Ex. B.) Although Paramount is not a party in the Escaldi Action, Escaldi seeks to recover damages because Paramount lost American Consultants as a customer. (Defs.’ Mem. Supp. Ex. B, Am. Countercl. ¶¶ 34–41.) {15} Agelity filed its second New York action on April 30, 2012, styled Agelity, Inc. v. Sallusto, No.: 12-13366 (N.Y. filed Apr. 30, 2012) (the “Sallusto Action”).1 (Defs.’ Mem. Supp. Ex. C.) In that action, both Paramount and Escaldi are defendants. Agelity complains that Paramount was formed through Escaldi’s breaches of duties and through trade secret misappropriation, and that thereafter Paramount unfairly competed and wrongfully solicited Agelity’s customers. Defendants did not assert any counterclaims. (See Defs.’ Mem. Supp. Ex. D.)

1 The full list of defendants consists of Michael Sallusto, Philip Escaldi, Kenneth Hammond, Jeremy

Starrin, and Paramount Rx., Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lawyers Mutual Liability Insurance v. Pollard
435 S.E.2d 571 (Court of Appeals of North Carolina, 1993)
Home Indemnity Co. v. Hoechst-Celanese Corp.
393 S.E.2d 118 (Court of Appeals of North Carolina, 1990)
Motor Inn Management, Inc. v. Irvin-Fuller Development Co.
266 S.E.2d 368 (Court of Appeals of North Carolina, 1980)
Wachovia Bank v. Harbinger Capital Partners Master Fund I, LTD.
687 S.E.2d 487 (Court of Appeals of North Carolina, 2009)
Nutrition & Fitness, Inc. v. Blue Stuff, Inc.
264 F. Supp. 2d 357 (W.D. North Carolina, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
2015 NCBC 30, Counsel Stack Legal Research, https://law.counselstack.com/opinion/paramount-rx-inc-v-duggan-ncbizct-2015.